Carcinoma, Non-Small-Cell Lung
Showing NaN - NaN of 48
NSCLC, Tumor Metastasis Trial in Worldwide (LY3537982, Pembrolizumab, Placebo)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Neoplasm Metastasis
- LY3537982
- +5 more
-
Tucson, Arizona
- +217 more
Nov 1, 2023
NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Lazertinib
- +3 more
-
Los Angeles, California
- +83 more
Jan 31, 2023
NSCLC Trial in Worldwide (Nivolumab, Carboplatin, Cisplatin)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Nivolumab
- +6 more
-
Tampa, Florida
- +112 more
Jan 30, 2023
NSCLC Trial in Worldwide (Alectnib, Cisplatin, Vinorelbine)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Alectnib
- +5 more
-
Chicago, Illinois
- +140 more
Jan 20, 2023
NSCLC Trial in Worldwide (Sasanlimab Prefilled syringe, Encorafenib, Binimetinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Sasanlimab Prefilled syringe
- +5 more
-
Duarte, California
- +96 more
Jan 18, 2023
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, NSCLC Trial (JDQ443, trametinib, Ribociclib)
Recruiting
- KRAS G12C Mutant Solid Tumors
- +10 more
- JDQ443
- +3 more
-
Boston, Massachusetts
- +5 more
Jan 11, 2023
NSCLC Trial in Worldwide (INC280 (capmatinib))
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- INC280 (capmatinib)
-
Long Beach, California
- +95 more
Dec 29, 2022
NSCLC Trial in Worldwide (Selpercatinib, Placebo)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Selpercatinib
- Placebo
-
Santa Monica, California
- +206 more
Dec 27, 2022
NSCLC Trial in Worldwide (Durvalumab, Placebo, Osimertinib (single-arm, open-label))
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Durvalumab
- +2 more
-
Tuscaloosa, Alabama
- +260 more
Dec 16, 2022
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide
Active, not recruiting
- RET-altered Non Small Cell Lung Cancer
- +39 more
- pralsetinib (BLU-667)
-
Phoenix, Arizona
- +65 more
Nov 10, 2022
NSCLC Trial in Boston, New York (MPDL3280A, Carboplatin, Nab-paclitaxel)
Completed
- Carcinoma, Non-Small-Cell Lung
- MPDL3280A
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 12, 2022
Tumors, NSCLC, Pancreatic Tumors Trial in Worldwide (V941, Pembrolizumab)
Completed
- Neoplasms
- +3 more
- V941
- Pembrolizumab
-
Gilbert, Arizona
- +25 more
Sep 5, 2022
Lung Tumors, NSCLC Trial in Worldwide (biological, drug, radiation)
Recruiting
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Pembrolizumab
- +9 more
-
Mobile, Alabama
- +194 more
Aug 18, 2022
NSCLC, Colorectal Neoplams, Endometrial Tumors Trial in Worldwide (LY3537982, Abemaciclib, Erlotinib)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- +4 more
- LY3537982
- +7 more
-
Los Angeles, California
- +21 more
Jul 22, 2022
KRAS G12C Mutant Solid Tumors, NSCLC, Carcinoma, Colorectal Trial in Worldwide (JDQ443, TNO155, tislelizumab)
Recruiting
- KRAS G12C Mutant Solid Tumors
- +9 more
- JDQ443
- +2 more
-
Atlanta, Georgia
- +31 more
Jul 7, 2022
NSCLC Trial in Worldwide (Lorlatinib, Crizotinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
-
Altamonte Springs, Florida
- +164 more
May 27, 2022
Stage IV NSCLC, Targeted Therapy, Nonsmall Cell Lung Cancer Trial in Boston (POISE)
Not yet recruiting
- Stage IV Non-small Cell Lung Cancer
- +7 more
- POISE
-
Boston, MassachusettsMassachusetts General Hospital
Apr 13, 2022
NSCLC, Solid Tumor Trial in Boston (Merestinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Solid Tumor
-
Boston, Massachusetts
- +1 more
Jan 26, 2022
Triple-Negative Breast Tumors, NSCLC, Head and Neck Carcinoma, Squamous Cell Trial in Worldwide (TAK-659, Nivolumab)
Terminated
- Triple-Negative Breast Neoplasms
- +3 more
-
La Jolla, California
- +21 more
Mar 18, 2020